NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design to Report Third Quarter 2016 Financial Results & Present at Upcoming Investor Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results after the close of U.S. financial markets on Wednesday, Nov.
View HTML
Toggle Summary Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical
View HTML
Toggle Summary Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development
Partner Sanofi commences dosing in peanut allergy Phase 1 trial leveraging GLAAS
View HTML
Toggle Summary Immune Design Prices Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $6.25 per share.
View HTML
Toggle Summary Immune Design Announces Proposed Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design.
View HTML
Toggle Summary Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2016 Financial Results
SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report second quarter 2016 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company's Board of Directors. Dr.
View HTML
Toggle Summary Immune Design Releases New PFS, OS and TME Data from Trials of Three Immuno-Oncology Product Candidates
LV305, CMB305 and G100 Data at ASCO and June 8 NYC Update Event
View HTML
Toggle Summary Immune Design Announces Upcoming Events
- Jefferies 2016 Healthcare Conference Presentation - - Company Update Webcast June 8 in New York - SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced two upcoming events
View HTML